JP2010505869A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505869A5
JP2010505869A5 JP2009531568A JP2009531568A JP2010505869A5 JP 2010505869 A5 JP2010505869 A5 JP 2010505869A5 JP 2009531568 A JP2009531568 A JP 2009531568A JP 2009531568 A JP2009531568 A JP 2009531568A JP 2010505869 A5 JP2010505869 A5 JP 2010505869A5
Authority
JP
Japan
Prior art keywords
composition
group
disease
treating
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009531568A
Other languages
English (en)
Japanese (ja)
Other versions
JP5362572B2 (ja
JP2010505869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/080231 external-priority patent/WO2008042921A2/en
Publication of JP2010505869A publication Critical patent/JP2010505869A/ja
Publication of JP2010505869A5 publication Critical patent/JP2010505869A5/ja
Application granted granted Critical
Publication of JP5362572B2 publication Critical patent/JP5362572B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009531568A 2006-10-02 2007-10-02 テトラ−o−置換ブタン架橋修飾ndga誘導体、それらの合成および薬学的使用 Expired - Fee Related JP5362572B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82778306P 2006-10-02 2006-10-02
US60/827,783 2006-10-02
PCT/US2007/080231 WO2008042921A2 (en) 2006-10-02 2007-10-02 Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010505869A JP2010505869A (ja) 2010-02-25
JP2010505869A5 true JP2010505869A5 (enExample) 2011-11-17
JP5362572B2 JP5362572B2 (ja) 2013-12-11

Family

ID=39269174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531568A Expired - Fee Related JP5362572B2 (ja) 2006-10-02 2007-10-02 テトラ−o−置換ブタン架橋修飾ndga誘導体、それらの合成および薬学的使用

Country Status (6)

Country Link
US (4) US8232277B2 (enExample)
EP (1) EP2076125B1 (enExample)
JP (1) JP5362572B2 (enExample)
CN (1) CN101547602B (enExample)
ES (1) ES2449237T3 (enExample)
WO (1) WO2008042921A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011117A2 (ko) * 2008-07-25 2010-01-28 국립암센터 Ndga를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2012145749A1 (en) 2011-04-22 2012-10-26 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
US9084779B2 (en) * 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
WO2022159326A1 (en) 2021-01-19 2022-07-28 Erimos Pharmaceuticals, Llc Terameprocol and nordihydroguaiaretic acid (ndga) derivatives as coronavirus anti-viral agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
EP0289506A4 (en) * 1986-11-19 1990-12-12 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
EP0290442A4 (en) * 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
AU2003237379A1 (en) * 2002-06-10 2003-12-22 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
ES2536177T3 (es) * 2005-01-27 2015-05-21 Erimos Pharmaceuticals Llc Formulaciones para la inyección de butanos catecólicos, incluyendo compuestos de NDGA, en animales
US7741357B1 (en) * 2006-04-17 2010-06-22 Johns Hopkins University Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents

Similar Documents

Publication Publication Date Title
JP2010505865A5 (enExample)
JP2010505869A5 (enExample)
JP2012525393A5 (enExample)
JP2021063088A5 (enExample)
JP2020507589A5 (enExample)
JP2008543854A5 (enExample)
JP2018518537A5 (enExample)
JP2013508279A5 (enExample)
JP2004516314A5 (enExample)
JP2017537940A5 (enExample)
JP2015511638A5 (enExample)
JP2016534063A5 (enExample)
JP2016512202A5 (enExample)
JP2006506425A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2009502743A5 (enExample)
CN113993860A (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
JP2015537020A5 (enExample)
JP2013512277A5 (enExample)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2016531126A5 (enExample)
JP2014530838A5 (enExample)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
JP2016528273A5 (enExample)